Dihexa
/ Synthetic hexapeptide; angiotensin IV analogALIAS · PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Terms in this page you can click for a plain-English popup: , , , , , , , .
No human trials have been published. Rodent preclinical data only. Theoretical oncogenicity concerns via HGF/c-Met pathway potentiation warrant explicit flagging.
Dihexa is a synthetic hexapeptide analog of angiotensin IV, developed by Joseph Harding’s lab at Washington State University. Proposed mechanism: potentiation of hepatocyte growth factor (HGF)/c-Met receptor signaling, promoting synaptogenesis and dendritic spine formation. Notable for claimed oral bioavailability and CNS penetration (rare among peptides).
None. No human trials have been published in peer-reviewed literature. ClinicalTrials.gov shows no entries for Dihexa. All data are rodent or in vitro.
No human safety data. Theoretical concerns about HGF/c-Met potentiation and oncogenic signaling (c-Met is implicated in multiple cancers) have been raised but not systematically studied for Dihexa specifically.
Regulatory status
- FDA status:
- Not FDA-approved
Small preclinical footprint, no human data, and a plausible theoretical oncogenicity signal from HGF/c-Met pathway potentiation that deserves explicit mention. Popular-press claims of "extraordinary" potency are not supported by clinical data because there is none.